title: [Proteins of resistance and drug resistance in ovarian carcinoma patients].
abstract: BACKGROUND
  To evaluate the correlation of resistance proteins LRP (Lung Resistance Protein), Pgp (P-glycoprotein), MRP (Multidrug Resistance-Associated Protein), MRP3 a MRP5 with stage, grade and histological type. To asses correlation of these resistance proteins with drug resistance/drug sensitivity in vitro by means of the MTT assay in ovarian cancer patients. To find the clinical outcome of these data.
  
  
  METHODS
  64 women with epithelial ovarian cancer who underwent primary surgery in 2006-2010 had specimens stained with immunohistochemistry for LRP, MRP, MRP3, MRP5 and Pgp and MTT assay (MTT-(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide).
  
  
  RESULTS
  Patients with late ovarian cancer had a higher Pgp, MRP, MRP3 and MRP5 level compared to ovarian cancer patients with early stage ovarian cancer. No correlation of resistance proteins with grading was found. Patients with high Pgp and MRP expression had significantly shorter progression-free survival. Patients with drug resistance in vitro by means of the MTT assay had higher Pgp and MRP expression.
  
  
  CONCLUSIONS
  P-glycoprotein and MRP may be useful predictor for outcome of primary chemotherapy in patients with ovarian cancer.
authors.affiliation: Porodnicka a gynekologicka klinika LF UK a Fakultni nemocnice Hradec Kralove, prednosta doc. sedlakiva@seznam.cz
authors.forename: I
authors.initials: I
authors.lastname: Sedláková
authors.forename: J
authors.initials: J
authors.lastname: Laco
authors.forename: J
authors.initials: J
authors.lastname: Tošner
authors.forename: K
authors.initials: K
authors.lastname: Caltová
authors.forename: M
authors.initials: M
authors.lastname: Cervinka
authors.forename: A
authors.initials: A
authors.lastname: Rezáč
authors.forename: J
authors.initials: J
authors.lastname: Spaček
authors.forename: P
authors.initials: P
authors.lastname: Skapinec
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000378:metabolism*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D020394:Vault Ribonucleoprotein Particles / Q000378:metabolism*; D000099187:Major Vault Protein
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein